Jimenez: "Huge Sense Of Urgency" To Implement Outcomes-Based Systems In Europe

Joe Jimenez, CEO of Novartis and EFPIA president talks about why the acceleration towards an outcomes-based healthcare system is so important to Europe, and to the reputation of the pharmaceutical industry.

Europe

It is "very frustrating for my industry to see all of the incredible innovation that is coming to market and not reach European patients, or patients in general where healthcare systems are under pressure," says Joe Jimenez, talking exclusively to Scrip at the European Federation of Pharmaceutical Industries and Associations' (EFPIA) annual conference.

EFPIA's outcomes-driven message is centered on the idea of improving health in a holistic and evidence-based way by evolving healthcare...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Pricing

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.